GlassScriptPhysician profile
Christopher A Chan
NPI 1972998730
$50,759.07
in general payments reported to CMS, 2019-2025
31 companies · $46K in 2025
The $46K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $26.65 · 2021: $144 · 2022: $946 · 2023: $1,162 · 2024: $1,371 · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Consulting Fee: $6,404 · Food and Beverage: $6,040 · Travel and Lodging: $2,300 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,218.00 |
| Consulting Fee | $6,403.95 |
| Food and Beverage | $6,039.84 |
| Travel and Lodging | $2,300.48 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34,855.85 | 2021-2025 | Breztri, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,181.96 | 2019-2025 | Ofev |
| Genzyme Corporation | $4,208.77 | 2021-2025 | |
| Glaxosmithkline, LLC. | $909.14 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $443.03 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Inari Medical, INC. | $381.50 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Insmed, INC. | $226.54 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $199.06 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $147.45 | 2022-2024 | Yupelri |
| Fisher Scientific Company L.L.C. | $139.81 | 2022 | |
| La Jolla Pharmaceutical Company | $131.49 | 2023-2025 | Giapreza |
| Verona Pharma, INC. | $120.58 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $103.73 | 2024-2025 | Purified Cortrophin Gel |
| Cumberland Pharmaceuticals, INC. | $88.57 | 2019 | |
| Amgen INC. | $88.50 | 2023-2025 | Tezspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $72.27 | 2023-2024 | |
| Baxter Healthcare | $57.09 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $54.01 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $51.72 | 2023 | Xywav |
| Viatris Specialty LLC | $50.95 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $41.09 | 2021-2025 | Glassia |
| Pulmonx Corporation | $30.58 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Inogen, INC. | $27.65 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Zoll Circulation INC | $26.65 | 2020 | |
| Adma Biomanufacturing LLC | $23.95 | 2025 | |
| Axsome Therapeutics, INC. | $23.15 | 2025 | Sunosi |
| Merck Sharp & Dohme LLC | $16.32 | 2024 | Capvaxive |
| Resmed Corp | $15.14 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $14.79 | 2022 | |
| Lilly USA, LLC | $14.22 | 2025 | Zepbound |
| Paratek Pharmaceuticals, INC. | $13.51 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.